This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: H49.8 | Special Copayment Reduction: V261 | Coverage period: 5 years |
| B. Synonyms | KSS, Kearns-Sayre disease, mitochondrial external ophthalmoplegia-retinitis pigmentosa-cardiac conduction abnormality syndrome, mitochondrial encephalomyopathy (some) |
| C. Adult onset | Low-to-moderate likelihood of first onset in adulthood — onset before age 20 is required by the diagnostic definition; however, there are cases with childhood onset that are diagnosed when the patient first presents in adulthood with cardiac complications |
| 1. History | First described by Kearns and Sayre in 1958; large-scale mtDNA deletion identified in 1988 |
| 2. Causes | Single large-scale mtDNA deletion (heteroplasmic); mostly sporadic de novo mutations; maternal inheritance rare |
| 3. Genetics | The 4977bp mtDNA deletion (common deletion) is the most common; 140~150 different deletions reported; heteroplasmy |
| 4. Epidemiology | Prevalence about 1~3/100,000; very rare; no sex difference; occurs in all races worldwide |
| 5. Pathophysiology | mtDNA deletion → oxidative phosphorylation (OXPHOS) deficiency → selective damage to energy-dependent tissues (muscle, heart, retina, nerves) |
| 6. Symptoms | Ptosis, external ophthalmoplegia, night blindness and visual field abnormalities, exercise intolerance, muscle weakness, syncope and arrhythmia symptoms |
| 7. Signs | Progressive external ophthalmoplegia, retinitis pigmentosa, complete atrioventricular block, cerebellar ataxia, elevated CSF protein |
| 8. Screening | Suspect KSS when the triad of ptosis + external ophthalmoplegia + retinitis pigmentosa is present; perform ECG and echocardiography immediately |
| 9. Diagnosis | Serum lactate, muscle biopsy (COX-deficient RRF), confirmation of mtDNA deletion (LR-PCR/NGS); CSF protein measurement |
| 10. Treatment | Complete atrioventricular block → pacemaker implantation essential; coenzyme Q10, riboflavin; consider ptosis surgery |
| 11. Prognosis | Cardiac conduction abnormalities are the main cause of death; survival can be prolonged after pacemaker insertion; slowly progressive |
| 12. Prevention | Primary prevention difficult because of sporadic de novo mutations; prevention of sudden death by early pacemaker insertion; regular ECG follow-up |
| References | 10 key references with PMIDs |
Kearns-Sayre Syndrome (KSS) became known in 1958 when the American ophthalmologist Thomas P. Kearns and the neurologist George P. Sayre first described two patients presenting with progressive external ophthalmoplegia, retinitis pigmentosa and cardiac conduction abnormalities together. Kearns and Sayre proposed this clinical triad as an independent syndrome, and with subsequent case reports, cerebellar ataxia, elevated cerebrospinal fluid protein, endocrine abnormalities, etc. were also recognized as major accompanying findings.
1988 was a landmark turning point in the understanding of KSS. As Holt et al. and Lestienne et al. independently discovered large-scale deletions in skeletal muscle mitochondrial DNA (mtDNA) of KSS patients, KSS was shown to be a mitochondrial disease caused by deletion of the mitochondrial genome. The most common deletion is the "common deletion" covering an approximately 4,977 base pair (bp) segment of mtDNA, and this deletion is commonly found in KSS, chronic progressive external ophthalmoplegia (CPEO) and Pearson syndrome (Pearson marrow-pancreas syndrome).
Subsequent research confirmed that KSS, CPEO and Pearson syndrome are a spectrum of diseases that originate from the same large-scale mtDNA deletion, with the phenotype determined by differences in the degree of heteroplasmy and tissue distribution. Pearson syndrome sometimes presents with bone marrow failure in infancy and, if the patient survives, progresses to KSS, so the clinical continuity between them has drawn attention.
The cause of KSS is a single large-scale deletion (SLSD) of mitochondrial DNA (mtDNA). In almost all cases the deletion exists in a heteroplasmic state; that is, normal mtDNA and deleted mtDNA coexist within the same cell or tissue. For symptoms to appear, the proportion of deleted mtDNA (heteroplasmy level) must exceed a certain threshold.
Most cases (about 90% or more) arise from sporadic de novo mutation, and maternal inheritance is very rare. This is because women with a large-scale mtDNA deletion transmit the variant to their children at a low frequency, and a mechanism of selective elimination of germline mtDNA (bottleneck) is presumed to be involved. Therefore, recurrence of the same disease in children of KSS patients is rare.
The deletion occurs early in embryonic development, and if the deleted mtDNA generated at this time proliferates predominantly in certain tissues, those tissues show selectively high heteroplasmy. In tissues with high energy consumption (myocardium, extraocular muscles, retina, cerebellum, basal ganglia, inner ear, etc.), impaired oxidative phosphorylation due to accumulation of deleted mtDNA manifests as clinical symptoms. The deletion proportion in peripheral blood leukocytes may be lower than in skeletal muscle, so the diagnostic sensitivity of blood testing alone is low.
The most common mtDNA deletion in KSS is the so-called "common deletion," in which about 4,977 bp of the nt8469~13447 or nt8482~13460 segment of mtDNA is deleted. This deletion removes a segment containing subunits of complexes I, III and IV and several tRNA genes. However, this 4977 bp deletion is not specific to KSS and is also found in CPEO and Pearson syndrome.
To date, more than 140~150 single large-scale deletions of various sizes and locations have been reported in KSS patients. Deletion sizes range from about 1.3 kb to more than 8 kb, and while deletion location and size affect the phenotype, a clear genotype-phenotype correlation has not been established. Direct repeat sequences at the deletion sites are known to be related to a mechanism that facilitates deletion formation.
The heteroplasmy level differs between tissues, and skeletal muscle generally shows the highest deletion proportion. Because the deletion proportion in peripheral blood is low and false negatives can occur, analysis of muscle biopsy tissue is the standard when there is strong clinical suspicion. Diagnostic methods used include long-range polymerase chain reaction (LR-PCR), next-generation sequencing (NGS), multiplex ligation-dependent probe amplification (MLPA) and Southern blot.
KSS is a very rare disease; accurate prevalence data are limited, but it is estimated at about 1~3/100,000. There is no sex difference, and it occurs in all races worldwide. KSS is the most clinically well-defined form in the spectrum of mitochondrial diseases caused by single large-scale mtDNA deletions. Chronic progressive external ophthalmoplegia (CPEO, due to mtDNA deletions or nuclear gene variants), which belongs to the same spectrum, is more common than KSS.
By the diagnostic definition, the age of onset is before 20, and in practice most cases are first suspected in childhood or adolescence because of extraocular muscle symptoms or retinal findings. Because most cases are sporadic, there is often no family history, and it is important to suspect and diagnose it in children with the clinical triad. Cardiac conduction abnormalities are initially asymptomatic but carry a risk of sudden cardiac arrest, so cardiac evaluation must be performed immediately when KSS is diagnosed.
The life expectancy of KSS patients has improved compared with the past through appropriate cardiac management (pacemaker implantation) and multidisciplinary supportive care. However, considerable disability accumulates due to extensive multisystem involvement, and reduced quality of life and functional limitation are the main clinical problems. Early diagnosis and, in particular, preemptive management of cardiac conduction abnormalities are the most important factors for prognosis.
The core pathophysiology of KSS is impaired function of the oxidative phosphorylation (OXPHOS) complexes due to large-scale mtDNA deletion. mtDNA encodes subunits of OXPHOS complexes I, III, IV and V, as well as the 22 tRNAs and 2 rRNAs needed for their synthesis. A large-scale deletion simultaneously removes multiple complex subunit genes and tRNA genes, impairing the function of complexes I, III and IV in combination.
Impaired OXPHOS function reduces the cell's capacity to produce ATP, and damage appears selectively in tissues with high energy dependence. The extraocular muscles require high energy for high-frequency contraction, which is why external ophthalmoplegia appears as an early symptom. The retinal pigment epithelium and photoreceptors consume considerable energy to maintain the continuous visual cycle, so they are also damaged early. Cardiac conduction system cells depend on ATP to maintain automaticity, and OXPHOS failure causes progressive conduction disturbances.
As a secondary consequence of OXPHOS failure, excessive production of reactive oxygen species (ROS) occurs, which accelerates mitochondrial membrane damage and cell death. The "ragged red fiber (RRF)" observed on muscle biopsy is a histopathological finding reflecting proliferation of degenerated mitochondria within skeletal muscle and appears characteristically on modified Gomori trichrome staining. Muscle fibers with loss of COX (complex IV, cytochrome c oxidase) activity are observed within RRFs.
The symptoms of KSS consist of three essential findings and one or more additional findings. The essential triad is ① onset before age 20, ② progressive external ophthalmoplegia (PEO) and ③ retinitis pigmentosa, and in addition, one or more of ④ cardiac conduction abnormalities (complete atrioventricular block or bundle branch block, etc.), ⑤ elevated cerebrospinal fluid protein (>100 mg/dL) and ⑥ cerebellar ataxia is required.
External ophthalmoplegia is bilateral with restricted eye movements, and ptosis precedes or accompanies it. Most cases progress slowly, beginning with limitation of upward gaze and later developing into complete external ophthalmoplegia. Diplopia is rarer than in adult acquired external ophthalmoplegia because the symptoms in both eyes progress symmetrically. Night blindness, constriction of the peripheral visual field and progressive visual loss due to retinitis pigmentosa findings appear. However, these retinal findings are often milder and show an atypical pattern, unlike typical autosomally inherited RP.
Cardiac conduction abnormalities may begin with PR interval prolongation and bundle branch block and progress to complete atrioventricular block, at which stage syncope, dizziness and dyspnea on exertion appear. Cerebellar ataxia manifests as gait disturbance, speech disturbance (dysarthria), limb ataxia, etc. Other symptoms include sensorineural hearing loss, muscle weakness, diabetes (impaired insulin secretion), short stature, dementia and seizures. Renal tubular acidosis, including Fanconi syndrome, has also been reported.
Ophthalmic signs include bilateral symmetrical ptosis, restricted eye movements (external ophthalmoplegia) and pigmentary changes of the fundus. The retinitis pigmentosa findings are often more diffuse and subtle than the bone spicule pigmentation of typical RP, and frequently appear in a "salt-and-pepper" pattern. The ERG is usually reduced, but the degree of loss varies. RPE spots of the fundus may appear not only in the periphery but also in the macula.
Electrocardiogram (ECG) abnormalities show a pattern progressing in the order of PR prolongation, right bundle branch block, left bundle branch block, left anterior hemiblock and complete atrioventricular block. Because complete atrioventricular block can cause life-threatening cardiac arrest, the need for pacemaker insertion must be evaluated immediately upon detection of ECG abnormalities. Echocardiography may show accompanying cardiomyopathy findings. Cerebellar function testing confirms bilateral cerebellar ataxia, and brain MRI may show increased T2 signal in the cerebellum and basal ganglia, white matter changes, etc.
Serum and CSF tests show elevated lactic acid. Serum lactate may be elevated even at rest and increases more markedly after exercise. Elevated pyruvate and an elevated lactate/pyruvate ratio are also indirect indicators of mitochondrial dysfunction. CSF protein above 100 mg/dL is one of the diagnostic criteria for KSS. On muscle biopsy, RRF (ragged red fiber) is identified with modified Gomori trichrome staining, and COX-negative muscle fibers are observed on COX/SDH double staining.
Large-scale population screening for KSS is not currently performed. Clinical screening consists of actively suspecting KSS and performing immediate evaluation in the following situations: ① bilateral ptosis or external ophthalmoplegia with onset before age 20, ② retinal pigmentary abnormalities accompanied by extraocular muscle findings, and ③ unexplained cardiac conduction abnormalities (atrioventricular block or bundle branch block) in children and adolescents without a family history.
In all patients suspected of KSS, an electrocardiogram (ECG) is a test that must be performed immediately. If complete atrioventricular block or a serious conduction abnormality is found, the need for pacemaker insertion must be evaluated immediately; this is the most important life-saving intervention. Metabolic screening including serum lactate, pyruvate, creatine kinase (CK), amino acids and liver function tests is also performed when suspected. Ophthalmic examination (fundus examination, ERG, OCT, visual field testing) and hearing tests are performed concurrently.
Because children with a history of Pearson syndrome sometimes progress to KSS as they grow, survivors of Pearson syndrome should receive regular KSS-related multisystem monitoring. Confirmation requires muscle biopsy or mtDNA deletion analysis in blood/urine.
The diagnostic criteria for KSS consist of confirmation of the clinical triad and molecular genetic demonstration of an mtDNA deletion. As clinical criteria, ① onset before age 20, ② progressive external ophthalmoplegia and ③ retinitis pigmentosa are essential, and one or more of ④ complete atrioventricular block or other conduction abnormalities, ⑤ CSF protein >100 mg/dL and ⑥ cerebellar ataxia must be added.
Molecular genetic confirmation is made by mtDNA deletion analysis of skeletal muscle biopsy tissue. LR-PCR (long-range PCR) is the first-line method for rapidly confirming the presence of a deletion. To determine the size and boundaries of the deletion accurately, NGS-based mitochondrial genome analysis or Southern blot is used. Analysis of peripheral blood DNA may give false negatives, so caution is needed in interpreting results, and if clinical suspicion is strong, muscle biopsy must be performed even if the blood test is negative. MLPA is useful for additional confirmation of a deletion.
Ancillary tests include muscle biopsy histopathology (RRF on modified Gomori trichrome staining, COX-negative muscle fibers on COX/SDH double staining), measurement of respiratory chain enzyme activity, serum and CSF lactate, brain MRI (increased white matter T2 signal, basal ganglia abnormalities), ECG, Holter monitoring, echocardiography, hearing tests, endocrine function tests (glucose tolerance, thyroid, parathyroid) and renal function tests. After diagnosis, the extent of damage to each organ is recorded as a baseline, and a regular follow-up plan is established.
There is currently no curative treatment for KSS, and treatment focuses on symptomatic management of each organ complication and prevention of life-threatening complications. Management of cardiac conduction abnormalities is most important. When complete or high-grade atrioventricular block is confirmed, permanent pacemaker implantation is essential. Pacemaker insertion greatly reduces the risk of sudden death and is the most effective intervention for prolonging survival in KSS patients. If there is a risk of ventricular tachycardia or ventricular fibrillation, insertion of an implantable cardioverter-defibrillator (ICD) is also considered.
As supplementation to support mitochondrial function, coenzyme Q10 (ubiquinone, 300~1,200 mg/day), riboflavin (vitamin B2, 100~400 mg/day), L-carnitine, vitamin C, vitamin E, thiamine (vitamin B1), etc. are commonly given. However, there are as yet no high-quality randomized controlled trials proving the KSS-specific clinical efficacy of these supplements, and they are prescribed on empirical grounds. Coenzyme Q10 has a theoretical rationale of supplementing its role in transferring electrons between complexes I·II and III in the electron transport chain.
When ptosis is severe, frontalis sling or levator palpebrae superioris resection may be performed, but because the corneal reflex may be reduced in KSS, the decision is made carefully considering the risk of exposure keratopathy. Low vision rehabilitation (prescription of aids, mobility training) is provided for retinitis pigmentosa. When diabetes is present, insulin or oral hypoglycemic agents are used, but metformin is avoided due to the increased risk of lactic acidosis. Metabolic complications such as renal tubular acidosis and hypocalcemia are managed with appropriate electrolyte and metabolic correction for each.
The prognosis of KSS depends greatly on the presence of cardiac conduction abnormalities and whether they are appropriately managed. In the era before pacemaker insertion, Adams-Stokes attacks and sudden death due to complete atrioventricular block were the main causes of death. Survival has improved significantly since pacemaker implantation, but the progression of multisystem complications cannot be prevented. Mean survival has been extended to several decades or more, and some patients have been reported to survive into their 40s~50s.
Visual prognosis varies with the degree of progression of retinitis pigmentosa, and in most cases worsens gradually. Night blindness and constriction of the peripheral visual field gradually intensify, and central vision may also decrease in the late stage. Cerebellar ataxia gradually worsens over time, increasing gait disturbance and the risk of falls. Cognitive decline and dementia also progress in some patients. Patients who progressed from Pearson syndrome to KSS tend to show more severe multisystem complications than typical KSS patients.
Regular multidisciplinary follow-up (ophthalmology, cardiology, neurology, endocrinology, genetics, rehabilitation medicine) is essential for early detection and management of complications. There is no single indicator predicting the clinical course, and prognosis is determined by multiple factors such as heteroplasmy level, extent of damaged tissue and individual capacity to compensate in energy metabolism.
Because most KSS arises from sporadic de novo mtDNA deletions, primary prevention is practically difficult in the absence of a family history. Although maternally inherited cases are very rare, molecular genetic testing of the children of female KSS patients may be considered. Preimplantation genetic testing (PGT) is used only to a limited extent because, owing to the nature of mtDNA diseases, heteroplasmy levels are difficult to predict.
The key to secondary prevention is prevention of sudden death due to cardiac conduction abnormalities. In all patients diagnosed with KSS, an ECG is performed immediately, and thereafter ECG at least every 6~12 months and Holter monitoring when needed are performed to monitor progression of conduction abnormalities. Even before complete or high-grade atrioventricular block occurs, prophylactic pacemaker insertion is carefully considered if progressive conduction disturbance is confirmed. Even after pacemaker insertion, lead function and battery status are checked through regular follow-up.
Early detection and treatment are achieved through regular monitoring for metabolic complications such as diabetes, endocrine abnormalities and renal dysfunction. Drugs that can impair mitochondrial function (chloramphenicol, valproic acid, tetracycline, high-dose statins, metformin, etc.) are avoided where possible or used with careful monitoring. Patients and caregivers are educated about the clinical course of KSS, the risk of cardiac complications and how to respond to emergencies (immediately visiting a medical facility in case of syncope).